Health Condition 1: I50- Heart failure
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: Nil: Nil
Intervention5: Nil: Nil
Sponsors
Gunanidhi S
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient Diagnosed With Heart Failure Patients diagnosed based on European Society of Cardiology (ESC), American Heart Association (AHA), or American College of Cardiology (ACC) guidelines. Patients with clinical symptoms of heart failure such as dyspnea, edema, fatigue, and palpitations, confirmed by echocardiography, electrocardiogram, or traditional biomarkers including troponin and BNP. 2. Patients aged 18 years and above. 3. Patients receiving at least one guideline-directed medical therapy (GDMT) for heart failure. 4. Patients who have the capacity to understand the basic information about the research, are willing to participate in follow-up visits, and are able to provide informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with the following diseases that may potentially affect the serum levels of suPAR and VCAM-1 will be excluded: HIV infection COVID-19 Advanced lung disease Cirrhosis of liver Sepsis Bronchial asthma Rheumatoid arthritis Renal failure Tuberculosis Severe anaemia Severe chronic obstructive pulmonary disease (COPD) Acute coronary syndrome diagnosed within the past three months Chronic kidney disease stage four or five Focal segmental glomerulosclerosis 2. Patients diagnosed with any of the above exclusion conditions during the follow-up period will be excluded from further participation. 3. Patients undergoing major surgical procedures during the follow-up period will be excluded, considering the potential impact of surgical stress, systemic inflammation, and perioperative medications on serum biomarker levels. 4. Patients who are prescribed immunosuppressive medications. 5. Patients with recent use of methotrexate, azathioprine, prednisone, methylprednisolone, tacrolimus, cyclosporine, or colchicine for immunosuppressive or anti-inflammatory purposes. 6. Patients aged below 18 years. 7. Pregnant or breastfeeding women. 8. Patients who are unwilling or unable to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in serum supar and vcam-1 levels in heart failure patients receiving pharmacotherapyTimepoint: Baseline (at enrollment) Scheduled follow-up visits (at predefined intervals over a 1-year period) Final assessment at the last follow-up visit | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of baseline and follow-up levels of supar and vcam-1 with clinical outcomesTimepoint: Measured at baseline, 6th month and 12th month;Association between biomarker levels and other clinical parametersTimepoint: baseline and final follow-up, with interim correlations during scheduled follow-up visit | — |
Countries
India
Contacts
Public ContactVijayakumar T M
Srm institute of science and technology
Outcome results
None listed